Saudi summit: GLP-1 drugs could revolutionize global health, access remains a challenge
Speaking at the second annual Global HealthSpan Summit, organized by the Kingdom's Hevolution Foundation, David Bradley Allison raised crucial questions about the future of GLP-1 drugs, which have shown remarkable effectiveness in treating obesity and potentially extending healthy lifespans.
'Who decides who gets these drugs? Who pays for them?' Allison asked, addressing the ethical considerations surrounding access to these medications. 'Should a person be able to choose to take one of these drugs for their benefits that they perceive, even if it's not judged by mainstream medicine as medically indicated?' Allison questioned, highlighting the tension between personal choice and medical oversight.
Addressing concerns about the high cost of GLP-1 drugs, Allison drew parallels with other technologies that became more affordable over time.
'People talk about how it would cripple the economy, but these are predicated on assumptions that the price doesn't come down,' he said. 'Pocket calculators were very expensive in 1970. Now you give pocket calculators away.'
The researcher also noted ongoing developments in drug delivery systems, including oral medications currently in development as alternatives to injections, which could potentially increase accessibility and reduce costs.
While acknowledging the promise of GLP-1 drugs, Allison emphasized the importance of addressing broader social and economic factors affecting public health. He cited two significant studies demonstrating the impact of environmental and educational factors on obesity rates.
The Moving to Opportunity study, a long-term randomized controlled trial by the US Department of Housing and Urban Development, showed that people who moved to better housing conditions were less likely to develop obesity and diabetes decades later.
Similarly, the Abecedarian study revealed that early intervention programs focusing on education and parent training led to lower obesity rates, particularly among women and girls.
When asked about potential policy solutions, Allison advocated for a freedom-oriented approach rather than restrictions.
'I like giving things, not taking things,' he said, suggesting that government action should focus on making anti-obesity medications more accessible while ensuring proper informed consent.
The summit was organized by the Hevolution Foundation, established by Saudi Crown Prince Mohammed bin Salman through a royal decree. The foundation commits over one billion dollars annually to research aimed at extending healthy human lifespans, representing one of the largest investments in longevity science globally.
The non-profit foundation aims to democratize access to healthspan science to benefit all of humanity, marking a significant shift in Saudi Arabia's role in global health research.
The discussion comes at a time when GLP-1 drugs have gained significant attention for their effectiveness in treating obesity and potential implications for healthy aging.
These medications work by mimicking hormones that influence appetite, fullness, and digestion, representing a potentially transformative approach to treating obesity and related conditions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Makkah Newspaper
07-08-2025
- Makkah Newspaper
Saudi FDA Leading a Journey of Continuous Excellence and Development
Dear reader, according to recent reports and statistics from the Saudi Food and Drug Authority (SFDA), significant and remarkable developments have been achieved over the past few years across all regulated sectors. These developments have solidified the SFDA's standing as a leading regulatory body, not only in the region but also globally. This continuous advancement is part of broader efforts to improve and regulate pharmaceuticals, medical devices, and food products, sectors that are critically important to public health. SFDA is notably one of only three national regulatory bodies worldwide, alongside those of Singapore and South Korea, to have attained maturity level four (ML4) in the regulation of medicines and vaccines, according to the World Health Organization (WHO). Achieving this highest level of regulatory competency underscores the exceptional capabilities and efficiency of the SFDA. Furthermore, in 2023, the SFDA became the first Arab member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), an achievement that highlightsinternational trust in Saudi Arabia's pharmaceutical oversight capabilities. Additionally, the SFDA collaborates closely with prominent global organizations such as the International Medical Device Regulators Forum (IMDRF), the International Council for Harmonisation (ICH) of pharmaceuticals, and Codex Alimentarius, which ensures global food safety standards. These partnerships significantly contribute to harmonizing local and international regulatory systems and standards, enhancing the quality of healthcare and food products both within Saudi Arabia and internationally. The SFDA's regulatory role has notably expanded beyond its traditional functions of approving pharmaceuticals and medical devices. At the recent Global HealthSpan Summit held in Riyadh, Dr. Hisham Bin Saad Al-Jadhey, CEO of the Saudi Food and Drug Authority (SFDA), emphasized that the role of regulatory authorities has become increasingly comprehensive and influential. He explained that SFDA's responsibilities now extend beyond ensuring safety and efficacy to actively supporting innovation, adopting advanced health technologies, and regulating health practices that impact all aspects of the healthcare system. A key component of these broader responsibilities is the growing emphasis on the role of nutrition in public health. Recognizing Saudi Arabia's high incidence of chronic diseases such as diabetes and obesity, the SFDA has launched several practical initiatives aimed at reducing these health challenges. These include implementing clear labeling of calorie content, restricting salt content, and minimizing sugar and trans fats in food products. These initiatives are not limited to food alone but extend to incorporating modern health technologies into daily societal practices, significantly contributing to public health improvements and reducing hospital admissions related to chronic diseases. Moreover, the SFDA plays a crucial role in stimulating investment and growth within the regulated sectors by creating a safe and efficient regulatory environment that encourages innovation and product development. Balancing safety, efficiency, and innovation not only fosters growth in local healthcare industries but also enhances Saudi Arabia's global reputation as a leading investment and health destination. The importance of these developments is evident, as they significantly enhance Saudi Arabia's international standing and its attractiveness to global investors in the healthcare and food sectors. Furthermore, these advancements positively impact the national economy by creating new investment opportunities, generating high-quality jobs for citizens, and generally improving public health quality. Consequently, Saudi Arabia has become a global model in healthcare regulation and food and drug safety. In conclusion, dear reader, the continuous and significant achievements of the SFDA underscore the ambitious vision adopted by the Kingdom to establish an advanced healthcare system based on global best practices, fundamentally aimed at enhancing the quality of life and ensuring public health and safety. These ongoing efforts solidify Saudi Arabia's position as a leader in healthcare at both regional and global levels.
Saudi Gazette
15-07-2025
- Saudi Gazette
Health official warns against unsupervised use of weight-loss drugs like Ozempic, Mounjaro
Saudi Gazette report RIYADH — Saudi Deputy Minister of Health for Population Health, Dr. Abdullah Asiri, has issued a public warning against the unsupervised use of anti-obesity medications such as Ozempic and Mounjaro, emphasizing the serious health risks associated with misuse. In a post on his official X account, Dr. Asiri cautioned that reckless reliance on these drugs or drastic dietary changes — such as extreme calorie restriction or rigid vegan diets — can result in nutritional imbalances that negatively affect overall health. He noted that dietary supplements are generally unnecessary when one follows a well-balanced and complete diet. He also advised the public to avoid foods high in fat and irritating spices, and to incorporate regular physical activity, such as walking and exercise, into their daily routines to maintain a healthy lifestyle without resorting to quick fixes or risky solutions. His remarks come amid growing concern from medical professionals about the increasing popularity of weight-loss drugs being used without prescriptions, raising red flags over long-term safety and potential side effects.
Al Arabiya
09-07-2025
- Al Arabiya
Billion-dollar Saudi Hevolution Foundation brings world-first Hepatitis B cure to trials
A potential world-first cure for hepatitis B, a breakthrough treatment for a rare, life-threatening childhood disease, and a psoriasis treatment that could reshape healthy lifespan research – these are some of the real-world medical advances being driven by the Saudi Arabia-based and funded Hevolution Foundation, marking unprecedented progress in the fight against age-related diseases. In an exclusive interview with Al Arabiya English, Dr. Mehmood Khan, CEO of the Hevolution Foundation, revealed that all four companies – initially funded by the Kingdom's massive healthspan initiative – have successfully transitioned from pre-clinical animal testing to human trials. Khan describes this achievement as 'unusual' in biotech investment. 'That is unprecedented,' the CEO said, highlighting the foundation's unique approach of screening 500 companies before focusing initially on the four most promising candidates. 'It speaks to great science. It speaks to scientists and the entrepreneurs that had the idea to build a company around the technology. It speaks to our investment team that sourced these deals, and it speaks to my science team that did deep due diligence.' The breakthrough developments come five years after Saudi Crown Prince Mohammed bin Salman issued a royal decree establishing the Hevolution Foundation. He pledged up to one billion dollars annually for research aimed at extending healthy human lifespan and combating age-related diseases. Hepatitis B breakthrough could transform Gulf healthcare Among the most significant developments is a potential cure for hepatitis B, a disease which has emerged as a global epidemic, according to the World Health. WHO estimates that 254 million people were living with chronic hepatitis B infection in 2022, with 1.2 million new infections each year and no cure. The disease represents one of the leading causes of liver cancer when left untreated, making the potential breakthrough particularly significant for regional healthcare systems. Khan highlighted that hepatitis B remains a major health concern in the Gulf, adding that clinical trials are expected to include the region as the technology progresses. The company is taking an innovative approach by targeting the virus's epigenetic interaction with human cells, marking a fundamental shift in treating viral diseases. According to Khan, when a person is infected with a virus, it first gets into the cells and they begin to age quickly. Viruses 'hijack our own machinery and use that machinery to reproduce themselves. The cells they're hijacking get damaged,' Khan explained. This science transforms how we understand ourselves and the impact the work can have. 'It changes the way we think about these issues, because now you can actually intervene,' Khan added. Revolutionary psoriasis treatment opens healthy lifespan pathways Another company – Rubedo – funded by Hevolution has developed a topical treatment for psoriasis that targets the underlying aging processes in skin cells, potentially opening vast new markets for healthy lifespan applications. Currently, severe psoriasis cases are treated using methods that 'suppress the immune system, which has all sorts of side effects,' Khan explained. The new approach instead addresses the root cause by modifying the aging biological processes in affected cells. In psoriasis, the skin cells age rapidly and the skin becomes inflamed. 'That inflammatory process causes the symptoms and signs of psoriasis and damage,' Khan explained. 'One of our companies came at this and said, could we change the aging biological process in these cells and actually see if the psoriasis improves? So, you're not treating the consequence of it, but the underlying biological process.' The implications extend far beyond psoriasis treatment. 'Now imagine the aging process in the skin, and if you could mitigate that using a topical approach, I don't need to tell you what the market might look like,' Khan said, suggesting potential applications in the broader healthy lifespan field. He pointed out that a potential treatment could have widespread positive impacts similar to Ozempic or other GLP-1 drugs –originally developed for diabetes but now used for multiple medical conditions, including obesity. The topical treatment is currently being tested in humans to reduce the aging process of skin in patients with psoriasis. 'The first thing to do is test for toxicity in humans. We know it's safe in animals. That's why it moved to humans,' Khan said. 'It's now being tested in what we call phase one.' The key questions at this stage are whether the treatment remains safe, whether there are any early signs of effectiveness, and how it should be dosed. Phase two will involve testing on patients with the disease at different dosage levels, followed by a large-scale phase three trial. Life-saving treatment for rare childhood disease The third breakthrough involves a treatment for tuberous sclerosis, a rare seizure disorder affecting children that currently has no cure. Children with this condition may 'eventually die from kidney diseases or seizure disorders,' Khan said. The current treatment options force families into an impossible choice. 'Imagine the choice: a child continues to have seizures, or you give them a drug which mitigates the seizures but now has lots of toxicity, and there's no alternative,' Khan said. Hevolution-funded company Aeovian Pharmaceuticals has developed an alternative approach that could provide the benefits of existing treatments without the severe side effects. 'They're actually now ready to enter human trials,' Khan confirmed, with first human results expected within 12 to 18 months. The treatment works through the mTOR pathway, building on previous research with rapamycin-like drugs. 'The problem with rapamycin is it's actually an immunosuppressant used in transplant patients to stop you rejecting your organ, which has all sorts of side effects. That's why most people are not wanting to even try rapamycin,' Khan explained. 'If you could take the benefits of rapamycin and eliminate its baggage, then you'd have something transformative.' Foundation's growing global impact In recent years, Hevolution launched more than $400 million in research grants, supporting more than 200 global grants and more than 250 scientists worldwide, including scientists in Saudi Arabia. As the single-largest lead funder in the field, the foundation was also instrumental in the creation of the $101mn XPRIZE Healthspan competition, launched at the Global Healthspan Summit in 2023. Khan outlined the foundation's comprehensive approach: 'We're funding about 250 scientists around the world. We have long-term research partnerships. We have short term research projects as short as a year, as much as up to five years.' The foundation's Global Healthspan Summit has become 'by far the largest gathering of aging biology scientists, investors, leaders, etc., in the world for an organization that didn't exist five years ago,' Khan said. The summit attracted over 3,500 participants from 80 countries, representing what Khan called 'unprecedented' growth in the field. 'By any international criteria, it's a huge success,' Khan said. 'We saw unprecedented growth in registrations, attendees, and global representations – up big on all measures from our first summit.' The foundation operates on three core principles that Khan believes are essential for transforming the healthy lifespan research landscape. 'One is we want to convene the field. The second is we want to catalyze the progress of the science, so create the pipeline for science to move eventually to the marketplace, in the hands of clinicians. The third is to make this field attractive for investors, so that the private sector accelerates its move into the market. You need all three,' Khan explained. This strategy has already begun attracting additional investors to the companies Hevolution initially funded. 'What we did by design was to invest in companies that were in pre-clinical stage,' Khan explained. 'What that means is that we're testing their theories, their ideas, their science, their interventions or treatments in animals.' One of the significant challenges the foundation addresses is the lack of regulatory pathways for aging-related treatments. 'There's no regulatory path today that allows a drug to be developed for aging. No regulatory agency has yet created that path,' Khan said. However, he drew parallels to historical precedents where science advanced ahead of regulatory frameworks. Using statins as an example, he noted that these cholesterol-lowering drugs were initially only approved for patients who had already suffered heart attacks, before eventually becoming standard preventive treatments. 'When statins came to the market back in the 1980s…they were only approved to lower your cholesterol if you'd had a heart attack, so you'd actually have to have a heart attack first, and then you get treated with statins,' Khan said. Today, if someone has high cholesterol and is considered high-risk, doctors prescribe statins to prevent the first heart attack. Khan credits this shift to widespread usage and proven benefits after initial market approval. 'We started to see the benefit,' he said. Khan indicated that within 36 to 60 months, the hepatitis B treatment, currently – in phase one – could enter phase three trials, representing the final stage before potential market approval. For the psoriasis treatment, the company 'should start three different clinical programs in different conditions' next year, with the skin treatment serving as the initial proof of concept before expansion into other applications. Central to Hevolution's mission is ensuring that breakthrough treatments benefit all of humanity, not just wealthy individuals seeking life extension. The foundation's approach differs from typical celebrity-driven longevity trends. 'We haven't come at this to create a lot of sensationalism. That's not what Hevolution is about,' Khan stated. 'This is not about a lot of celebrities getting on social media telling you what they do for themselves to have impact. We're here to democratize the science and impact humanity. And in our mind, the best way to do that is not only fund the science, but identify the best startup technologies that are ready to now be invested in.' Global investment in healthspan science needed Rather than seeking to monopolize the healthy lifespan research space, Hevolution actively encourages other investors and organizations to enter the field. 'We don't compete with any fund in the world. We want the more the merrier,' Khan said. 'If five years from now, we're the smallest player in the space, we'll have been successful. The idea is not to keep the pie the same size and have Hevolution have a significant large voice. No, the idea is that we become like the 10th player in a much larger field.' This collaborative approach reflects the foundation's ultimate goal of creating a sustainable ecosystem for aging research that extends far beyond any single organization's capabilities. As the global population ages – with more than one billion people over age 60 today expected to double to two billion by 2050 – the importance of Hevolution's work continues to grow. The breakthrough treatments now entering human trials represent more than just medical advances; they demonstrate proof of concept for entirely new approaches to age-related diseases.
